



REFERENCES

Alving, B. M. (2003): How I treat heparin-induced thrombocytopenia and thrombosis. *Blood*; 101:31-37.

Amiral, J.; Bridey, F.; Wolf M, Boyer-Neumann, C.; Fressinaud, E.; Vissac, A.M.; Peynaud-Debayle, E.; Dreyfus, M. and Meyer, D. (2004): Antibodies to macromolecular platelet factor 4- heparin complexes in heparin-induced and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. *Am J Hematol*; 76:69 -73.

Anderson, C.B.; Hathaway, K. and Glase, C.J. (2006): Haemostasis and blood coagulation; Text book of medical physiology; Arther C Guyton 11th ed; Elsevier Saunders Company; 36:457-468.

Anthony, J. and Barry, S. (2001): Platelet morphology and biochemistry and function ; Ernest B, Lichtman A and Thomas J; Williams Hematology 5th ed; Mc Graw-hill inc; 21: 1161-8.

Arepally, G. and Cines, D.B. (2002): Pathogenesis of heparin induced thrombocytopenia and thrombosis. *Autoimmun Rev*; 1: 125-132.

Armstrong, P. (1997): Heparin in acute coronary syndrome: required for a heavy weight? *373*: 492-494.

Bates, S.M. and Weitz, J.I. (2000): The mechanism of action of thrombin inhibitors. *J Invasive Cardiol*; 12: Suppl F: 27F-32F.



- Bates, S.M. and Wertz, J.L. (2001):** Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. *Am J Cardiol*; 82(8B): 12-18.
- Bauer, K.A. and Hawkinsm, D.W. (2002):** Fondaparinux; a synthetic pentasaccharide: the first in new class of antithrombotic agents. *Cardiovascular drug Rev.*; 20: 37-52.
- Bittl, J.A.; Chaitman, B.R.; Feit, F.; Kimball, W. and Topol, E.J. (2001):** Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. *Am Heart J*; 142: 952-959.
- Bousser, M.G. and Buller, H.R. (2008):** Comparison of idraparinux with vit K antagonist for prevention of thromboembolism in patients with atrial fibrillation: a randomized open label.
- Brieger, D.B.; Mak, K.H.; Kottke-Marchant, K. and Topol, E.J. (1998):** Heparin-induced thrombocytopenia. *J Am con Cardio1*; 31:1449-1459.
- Bruce, D.; Spiess Jay Horrow, and Joel, A. Kaplan (2006):** Transfusion medicine and coagulation disorder; In Joel A. Kaplan , David L. Reich , Carol L. Lake , Steven N. Konstadt ; *Kaplan's Cardiac Anesthesia* 5th ed; Saunders; 29:952-975.
- Campell, and Neil, A. (2008):** platelets are pinched off cytoplasmic fragment of specialized bone marrow cells, *Biology*, 8th edition, London: Pearson education; 976: 312-361.

- Carol, A.; Anderew, D. and David, G. (1999):** Perioperative hemostasis and coagulopathy, Critical care medicine; 49: 589-606.
- Charles, S. and Sanford, J. (2006):** Haemostasis and thrombosis; Marshall A, Thomas J, Ernest B; Williams Hematology ^{7th} ed; Mc Graw-Hill inc.; 113:1833-42.
- Cheung, R.C. and Pollard, J.B. (2005):** High mortality rates in patients with advanced liver disease independent of exposure to general anesthesia. Chin aneth; 17: 172-176.
- Chew, D.P.; Bhatt, D.L. and Kimball, W. (2003):** Bivalirudin provides increasing benefits with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol; 92: 919-23.
- Chong, B.H. (1995):** Heparin-induced thrombocytopenia. Br J Haematol; 89: 431-9.
- Chong, B.H. and Magnani, H.N. (2004):** Danaparoid for the treatment of heparin induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia, 3rd ed. New York, NY: Marcel Dekker; 371-396.
- Correia, M.C. and Lacedra, H.R. (2008):** Platelet function and the Vonwillbrand factor in the hepatosplenic form of shistosomais mansonii. Trans. R. Soc. Med.; 10: 61-101.
- Dacie, J. and Lewis, S. (2001):** Practical Hematology 7th ed; Churchill Livingstone; Edinburg ux; 35 :520-37.



- Deitcher, S.R. and Carman, T.L. (2001):** Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med; 6: 113-19.
- Despotis, G.J.; Suminerfield, A. and Joist, J. (2000):** In vitro reversal of heparin effect with heparinase ; Anesth Analg; 79: 670-4.
- DiNadro, J.A. (1998):** Management of cardiopulmonary bypass; Anesthesia for cardiac surgery Text book 2nd ed; Appleton and Lange Books; Simon and Schuster company; 10:277-290.
- DiNardo, J. and Zvara, D.A. (2008):** Management of Cardiopulmonary Bypass; Anesthesia for Cardiac Surgery Text book ; 3rd ed; Blackwell Publishing inc; 10:323-374.
- Dinisio, M. and Harry, R. (2005):** Biiller: Direct Thrombin Inhibitors; D N Engl J Med; 353:1028-40.
- Edward, A.C. and Jan, R.C. (2000):** coagulation and haemostasis; in Salim MR; blood conservation in surgical patient; Baltimore Md; William and Winkins; 35:364-82.
- Eichler, P.; Budde, U. and Haas, S. (1998):** First workshop for detection of heparin-induced antibodies: validation of the heparin induced platelet activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost; 81: 625-9.
- Emmanuel de Maistre, and Yves Gruel, (2006):** Diagnosis and management of heparin induced thrombocytopenia; Can J Anesth; 53:123-134.



- Eriksson, B.L. and Borris, L.C. (2006):** A once daily oral direct factor Xa inhibitors; Rivaroxaban for thromboprophylaxis after total hip replacement. *Circulation*; 114: 2374-2381.
- Fabrizio, M. (2006):** Use of Ecarin Clotting Time (ECT) with Lepirudin Therapy in Heparin-Induced Thrombocytopenia and Cardiopulmonary Bypass; *J E T*; 33:117-125.
- Farger, G.; Cullberg, M.; Eriksson-Lepkowska, M.; Frison, L. and Eriksson, G. (2003):** Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. *Eur J Clin Pharmacol*; 59:283-9.
- Fausset, M.B.; Vogtlander, M. and Rogers, G.M. (2001):** Heparin induced thrombocytopenia is rare in pregnancy. *Am J Obstet Gynecol*; 185: 148-152.
- Fiore, L. and Deykn, D. (2001):** anticoagulant therapy; in Ernest B; Lichtman A, Collier, Thomas J: *Williams hematology* 5 th ed; Mc Graw-Hill inc; 34; 34; 1562-73.
- Fisher, K.G. (2002):** Hirudin in renal insufficiency. *Semin Thromb Hemost*; 28:467-82.
- Fondu, P. (1995):** Heparin associated thrombocytopenia: an update. *Acta Clin Belg*; 50: 343±57.
- Francis, J. and Drexler, A. (2003):** Frequency of heparin-platelet factor 4 antibodies in patients presenting to the emergency room with symptoms of thrombosis. *J Thromb Hemost*; I (supple): p 47.



Girolami, B.; Prandoni, P.; Stefani, P.M.; Tanduo, C.; Sabbion, P.; Eichler, P.; Ramon, R.; Baggio, G.; Fabris, F. and Girolami, A. (2003): The incidence of heparin induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. *Blood*; 101:2955-2959.

Gladwell, T. and Bivalirudin, (2002): a direct thrombin inhibitor. *Clin Ther*; 24: 38-57.

Gosselin, R.C.; Dager, W.E.; King, J.H.; Janatpour, K.; Mahackian, K.; Larkin, E.C. and Owings, J.T. (2004): Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. *Am J Clin Pathol*; 121: 593-595.

Gravlee, G.P.; Davis, R.F. and Utley, J.R. (2000): Platelet function and cardiopulmonary Bypass; *Cardiopulmonary Bypass Principle and Practice*; Williams and Winkins; 4: 55-92.

Greer, I.A. and Nelson, C. (2005): LMWH for thromboprophylaxis of venous thromboembolism in pregnancy: a systemic review of safety and efficacy. *Blood*; 106: 401-407.

Greinacher, A. (1997): Heparin associated thrombocytopenia. *Biomed Prog*; 7: 53-56.

Greinacher, A. and Lubenow, N. (2001): Recombinant hirudin in clinical practice: focus on lepirudin. *Circulation*; 103: 1479-84.

Greinacher, A. and Lubenow, N. (2002): Heparin induzierte Thrombozytopenie. *Die gelben Hefte*; 42: 61-70.



- Greinacher, A. and Warkentin, T.E. (2001):** Treatment of heparin-induced thrombocytopenia: an overview, in Warkentin TE and Greinacher A, Heparin-induced thrombocytopenia, 2nd ed. NY; 291-322.
- Greinacher, A. and Warkentin, T.E. (2004):** Treatment of heparin induced thrombocytopenia: an overview. Heparin induced thrombocytopenia, 3rd ed. NY: Marcel Dekker; 335-370.
- Greinacher, A.; Amiral, J. and Dummel, V. (1994):** Laboratory diagnosis of heparin induced thrombocytopenia and comparison of platelet aggregation test, heparin induced platelet activation test, and platelet factor 4-heparin enzyme linked immunosorbent assay. Transfusion; 34: 381-385.
- Greinacher, A.; Eicheler, P. and Lubenow, N. (2003):** Heparin induced thrombocytopenia: a meta analysis of 2 prospective studies to assess the value of parenteral treatment with lepirudin and its therapeutic PTT range. Blood; 96: 846-51.
- Greinacher, A.; Janssens, U.; Berg, G.; Bock, M.; Kwasny, H.; Kemkes-Matthes, B.; Eichler, P.; Volpel, H.; Potzsch, B. and Luz, M. (1999):** Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation; 100: 587-593.
- Greinacher, A.; Lubenow, N. and Eichler, P. (2003):** Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation; 108:2062-2065.



- Gustafsson, D. and Elg, M. (2003):** The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. *Thromb Res*; 109: Suppl 1:S9-S 15.
- Hauptmann, J. and Sturzebecher, J. (1999):** Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. *Thromb Res*; 93: 203-41.
- Hessler, K. (2008):** Autologous platelet rich fibrin matrix a cell therapy in the healing of chronic lower extremities ulcers, *Wound Rep.*; 16: 749-756.
- Hirsh, J. and Russel, D. (1996):** Treatment of venous thromboembolism. *Chest*; 89: 4265-4335.
- Hirsh, J.; Heddle, N. and Kelton, J.G. (2004):** Treatment of heparin induced thrombocytopenia: a critical review. *Arch Intern Med*; 164:361-369.
- Hourigan, L.A.; Waltes, D.L. and Keck, S.A. (2002):** Heparin induced thrombocytopenia: a common complication in cardiac transplant recipients. *J Heart Lung Transplant*; 21: 1283-1289.
- Huhle, G.U.; Hoffmann, X.; Song, L.C.; Wang, D.L.; Heene, and Harenberg, J. (1999):** Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. *Br. J. Haematol*; 106: 195- 201.



- Hull, R.; Delmore, T. and Genton, E. (1995):** Warfarin sodium versus low-dose heparin in the management of venous thrombosis, N Engl J Med; 18: 855-8.
- Jang, I.K. and Hursting, M.J. (2005):** When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation; 111: 2671-2683.
- Jeffrey, N.; Bott Reddy, K. and Krick, S. (2003):** Bivalrudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia; Ann Thorac Surg; 76: 273-275.
- Joseph, T.; Wayne, K. and Douglas, G. (2006):** Anesthesia for cardiovascular surgery; Text Book of clinical Anesthesiology ;Morgan GE 4th ed;Lange Medical book;McGraw-Hill Company (1);21 ;436-450.
- Kakkar, A.K. and Brrener, B. (2008):** Extended duration rivaroxaban for prevention of venous thromboembolism after total hip arthroplasty. Lancet; 327: 31-39.
- Kandrotas, R. J. (2001):** Heparin pharmacokinetic and Pharmacodynamics; Clin. Pharmacokinet; 22:359-74.
- Kathryn, H. (2005):** The management of patients with heparin induced thrombocytopenia who requires anticoagulant therapy: Chest; 127: 1-8.
- Kazuo, Tadao Akizawa, Y.; Oshihei Hirasawa and Tetsuzo A. (2003):** Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency; 18: 1623-1630.



- Kelton, J.G.; Hursting, M.J. and Lewis, B.E. (2003):** The predictors of clinical outcome in patients with heparin-induced thrombocytopenia. *J Thromb Hemost*; 1 (suppl): OC020.
- Koopman, M.M. and Buller, H.R. (2003):** Short-and long-acting synthetic pentasaccharides; *J Intern Med*; 254:335-342.
- Koster, A.; Chew, D.; Grundel, M.; Bauer, M.; Kuppe, H. and Spiess, B.D. (2004):** Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. *Anesth Analg*; 96:383-6.
- Koster, A.; Kuppe, H. and Mertzlufft, F. (1999):** R-hirudin rebound after CPB in patients with HIT (type II) *Anes Analg.*; 88: 160S.
- Koster, A.M.; Loebe, R.; Hansen, M.; Bauer, F.; Mertzlufft, H.; Kuppe, and Hetzer, R. (2000):** A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the act II device. 1. *Thorac. Cardiovasc. Surg.*; 119:1278-1283.
- Kutzung, G. (2000):** Basic clinical pharmacology; 283-59.
- Latham, P.A. F.; Revelis, G.P. ; Joshi, J.M.; DiMaio, and Jessen, M. E. (2000):** Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. *Anesthesiology*; 92:263-266.



- Leo, A. and Winteroll, S. (2003):** Laboratory Diagnosis of Heparin Induced Thrombocytopenia and Monitoring of Alternative Anticoagulants; clinical and diagnostic laboratory immunology; p. 731-740.
- Levine, R.L.; Hursting, M.J.; Drexler, A.; Lewis, B.E. and Francis, J.L. (2004):** Heparin induced thrombocytopenia in the emergency department. *Ann Emerg Med*; 44:511-515.
- Levy, J.H.; Cormack, J.G. and Morales, A. (2003):** Heparin neutralization by recombinant platelet factor 4 and protamine; *anesth Analg*; 89:335-7.
- Lewis, B.E. and Hursting, M.J. (2001):** Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. *Heparin-induced thrombocytopenia*. 2nd Ed. New York: Marcel Dekker, 381-407.
- Lewis, B.E.; Matthai, W.H.; Cohen, M.; Moses, J.W.; Hursting, M.J. and Leya, F. (2002):** Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. *Cathet Cardiovasc Intervent*; 57: 177-184.
- Lewis, B.E.; Wallis, D.E.; Berkowitz, S.D.; Matthai, W.H.; Fareed, J.; Walenga, J.M.; Bartholomew, J.; Sham, R.; Lerner, R.G.; Zeigler, Z.R.; Rustagi, P.K.; Jang, I.K.; Rifkin, S.D.; Moran, J.; Hursting, M.J.; Kelton, J.G.; for the ARG-911 Study Investigators (2001):** Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. *Circulation*; 103:1838-1843.



- Lewis, B.E.; Wallis, D.E.; Leya, F.; Hursting, M.J. and Kelton, J.G. (2003):** Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med; 163: I 849-1856.
- Liaw, P.C.Y.; Becker, D.L.; Stafford, A.R.; Fredenburgh, J.C. and Weitz, J.I. (2001):** Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem; 276:20959-65.
- Lubenow, N.; Kempf, R.; Eichner, A.; Eichlet, P.; Carlsson, L.E. and Greinacher, A. (2002):** Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest; 122:37-42.
- Mahaffey, K.W.; Lewis, B.E. and Wildermann, N.M. (2003):** The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invas Cardio; 15: 611-616.
- Maraganore J.M., Adelman B.A. and Hirulog, (1999):** a direct thrombin inhibitor for management of acute coronary syndromes. Cor Artery Dis; 7:438-448.
- Mattioli, A.V.; Bonetti, L.; Sternieri, S. and Mattioli, G. (2001):** Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital Heart J; 1:39-42.



- Merry, A.F.; Raudkivi, P. and White, H.D. (2004):** Anticoagulation with bivalirudin (a direct thrombin inhibitor) vs. heparin. A randomized trial in OPCAB grafts surgery. *Anesth Analg*; 93:SCA33.
- Messmore, H.L.; Jeske, W.P. and Wehrmacher, W.H. (2003):** Benefit risk assessment of treatments for heparin-induced thrombocytopenia. *Drug Saf*; 26:625-641.
- Mikhailov, D.; Young, He, Linhardt, R. J. (1999):** Heparin binding to PF 4 and growth related protein alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. *J Biol Chem*; 274: 25317- 29.
- Nand, S.; Wong, W.; Yeun, B. and Yetter, A. (1997):** Heparin induced thrombocytopenia with thrombosis: incidence, analysis of risk factors and clinical outcomes. *AM J Haematol*; 56: 12-26.
- Ortel, T. and Chong, B. (1998):** New treatment options for heparin-induced thrombocytopenia. *Seminars in hematology*; 35(4 Suppl 5):26-34.
- Peter, R.J. and Joyner, C. (2008):** The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction. *Eur Heart*; 29: 24-31.
- Peters, R.J. (2004):** Efficacy and bleeding complication among patients randomized to enoxaparin and UFH with NSTEMI. *JAWA*; 292: 89-96.



- Petersen, J.; Mahaffey, K.; Hasselbald, V. and Cohen, M. (2004):** Efficacy and bleeding complications among patient randomaized to enoxaparin or unfractionated heparin for antithrombin therapy in NSTEMI: a systematic overview. JAMA; 7: 89-96.
- Potzsch, B.; Madlener, K. and Seeling, C. (1997):** Monitoring of recombinant hirudin: assessment of plasma-based ecarine clotting time assay. Thromb Res; 86: 373-383.
- Pouplard, C.; May, M.A.; Regina, S.; Maakaroun, A.; Fusciardi, J. and Gruel, Y. (2002):** Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies [Abstract]. Blood; 100: 16a-7a.
- Pravinkumar, E. and Webster, N.R. (2003):** HITT and alternative anticoagulation: current concepts. Br J Anaesth; 90: 676-85.
- Range, H.P.; Dale, M.M.; Reiter, J.M. and Moon, P.K. (2003):** Haemostasis and thrombosis;Textbook of pharmacology 5th ed :Churchill Livingstone; 20:314-329.
- Rezaie, A.R. (2003):** Inhibition of factor Xa and the thrombonase complex: mechanism of inhibition and comparison with therapeutic heparins. Thrombo haemost; 21: 89-112.
- Rice, L.; Attisha, W.K.; Drexler. A. and Francis, J.L. (2002):** Delayed onset heparin induced thrombocytopenia. Ann Intern Med; 136: 210-215.



- Rish, L.; Fischer, J.E.; Herklotz, R. and Huber, A.R. (2004):** Heparin induced thrombocytopenia in paediatrics: clinical characteristics, therapy and outcomes. *Intens Care Med*; 30: 1615-1624.
- Robert, H.R.; Monroe, D.M. and Escobar, M.A. (2004):** current concepts in haemostasis; implications of therapy; *Anesth*; 100: 722-43.
- Rydel, T.J.; Raviehandran, K.G. and Tulinsky, A. (1990):** The structure of a complex of hirudin and human thrombin. *Science*; 249:277-80.
- Sarich, T.C.; Wolzt, M. and Eriksson, U.G. (2003):** Effects of ximelagatran, an oral direct thrombin inhibitor, rhirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. *J Am Coll CardioI*; 41:557-64
- Scardavu, (2003):** HIV related thrombocytopenia. *Blood Rev*; 16: 37-6.
- Scilli, T.M. and Mauro, V.F. (2002):** Pharmacology and clinical use of bivalirudin. *Ann Pharmacother*; 36: 1028-41.
- Seltzer, J.L. and Ggersor, J.L. (2004):** Decrease arterial pressure following heparin injection prior to CPB; *Acta Anesth Scand*; 23:575-8.
- Shahar Bar yosef, Heidi B. and Cozart, R.P. (2007):** preoperative low molecular weight heparin responsiveness during cardiac surgery; *Can J Anesth*; 54:107-113.
- Sheridan, D.; Carter, C. and Kelton, J.G. (1986):** A diagnostic test for heparin induced thrombocytopenia. *Blood*; 67: 27-30.



- Sheth, S.B.; DiCicco, R.A.; Hursting, M.J.; Montague, T. and Jorkasky, D.K. (2001):** Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. *Thromb Hemost*; 85: 435-440.
- Shigeta, O.; Kojna, H.; Hiramutsu, Y. and Jikuya, T. (1999):** Low dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass; *J. Thorac. Cardiovascular surg*; 188(2):354-60.
- Slaughter, T.F. and Mark, J.B. (2000):** Heparin mediated hypotension associated with cardiac surgery; *Anesth Analg*; 9: 766-7.
- Stickema, J. (1998):** heparin and its biocompatibility; *Clin. Nephrology*; 26: 53-8.
- Stoeling, R.K. (2002):** Anticoagulant. Physiology and phannacology of anesthesia 2nd ed; Philadelphia by JB Lippin; 27:466-477.
- Stoeling, R.K. and Dieroderf, S.F. (2005):** Anesthesia and coexisting disease 4th ed; New York; Churchill Livingston; 32: 490-492.
- Stratmann, G.; diSilva, A.M. and Tseng, E.E. (2004):** Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. *Aneth Anag*; 98: 1635-1639.
- Strauss, G. and Wehler, M. (2002):** Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements and outcome. *Crit care Med.*; 30:1756-1771.



- Swan, S.K. and Hursting, M.J. (200):** The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic or renal dysfunction *Pharmacotherapy*; 20: 318-329.
- Tomer, A. (1997):** Sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. *Br J Haematol*; 98: 648-656.
- Van de Werf, F. (2009):** New antithrombotic agents: are they needed and what can they offer to patients with NSTEMI? *Eu Heart Jo*; 230 VI-eh p 230.
- Vanholder, R.; Camez, A.; Veys, N. Van Loo, A.; Dhondt, A.M. and Rignoir, S. (1997):** Pharmacokinetics of recombinant hirudin in haemodialyzed patients. *Thromb Hemost*; 77: 50-65.
- Villaneuva, G.B. and Denishefsky, I. (2003):** Evidence for a heparin induced conformational change on antithrombin III; *Biochem Biophys Res Comm*; 74:803-9.
- Visentin, G.P. and Aster, R.H. (1995):** Heparin induced thrombocytopenia and thrombosis. *Curr Opin Haematol*; 2: 351-7.
- Walenga, J.M.; Koza, M.J. and Lewis, B.E. (1996):** Relative heparin induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. *Thromb Hemost*; 2(suppl 1):S21-S27.



- Walker, C.P.R. and Royston, D. (2002):** Thrombin generation and its inhibition; a review of scientific and mechanism of action of anticoagulant therapy; 32: 848-63.
- Wallis, D.E. Q.R.; Wehrmacher, W. and Messmore, H. (2004):** Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest; 116: 1333-8.
- Wallis, D.E.; Workman, D.L. and Lewis, B.E. (1999):** Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med; 106: 629-35.
- Warkentin, T. and Kelton, J. (2002):** Delayed onset heparin induced thrombocytopenia and thrombosis. Annals of internal medicine; 136: 210-215.
- Warkentin, T.E. (1998):** Limitation of conventional treatment options for heparin induced thrombocytopenia. Semin Haematol; 35 (supple 4): 17.
- Warkentin, T.E. (2000):** Heparin induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost; 82: 439-447.
- Warkentin, T.E. and Cook, D.J. (2005):** Low molecular weight heparin and heparin induced thrombocytopenia in the ICU. Crit, care; 21: 513-529.
- Warkentin, T.E. and Greinacher, A. (2004):** Heparin induced thrombocytopenia: pathogenesis and management: the 7th ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest; 126:311.



- Warkentin, T.E. and Greinacher, A. (2007):** Heparin induced thrombocytopenia: recognition, treatment and prevention. *Chest*; 126: 311-337.
- Warkentin, T.E. and Greinacher, A. (2003):** Heparin induced thrombocytopenia and cardiac surgery. *Annals of thoracic surgery*; 76: 683-48.
- Warkentin, T.E.; Aird, W.C. and Rand, J.H. (2003):** Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. *Haematol. Am Prog*; 128: 497-519.
- Warkentin, T.E. (2003):** Heparin induced thrombocytopenia: pathogenesis and management. *Br J Haematol*; 121: 535-550.
- Wasowicz, M.; Vegas, A.; Borger, M.A. and Harwood, S. (2005):** Bivalirudin anticoagulation for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia; *CAN J ANESTH*; 52: 10; pp 1093-1098.
- Weitz, J.I. (1997):** Low-molecular weight heparins. *N Engl J Med*; 337:688-698.
- Weitz, J.L. and Hirsh, J. (2004):** Antithrombins, their potential as anti thrombotic agents; *Annu. Rev. Med*; 43:9-16.
- Wilhelm, M.J.; Schmid, C. and Kececioghi, D. (1996):** Cardiopulmonary bypass in patients with heparin induced thrombocytopenia using Orgaran® 10172. *Ann Thorac Surg*; 61: 920-24.



Williams, R.T.; Damaraju, L.V.; Mascelli, M.A.; Barnathan. E.S.; Califf, R.M.; Simoons, M.L.; Deliargyris, E.N. and Sane, D.C. (2003): Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. *Circulation*; 107: 2307-2312.

